Biopharma has finally begun catching up with the overall stock market, if the positive returns shown by the top three exchange traded funds (ETFs) since the spring are any indication. Over the past six months, shares of the top three biopharma ETFs have jumped well into double digits. The top biotech-focused ETF with $6.562 billion…
In This Story If you thought last week was a heavy one for markets — big intraday swings, shifting sentiment — just wait. Another packed slate of earnings and economic data is on the way, offering one of the clearest views into the health of American business yet this year. Think Amazon (AMZN), Meta (META),…
Burlington Stores (BURL) and Air Lease (AL) are the latest additions to Goldman Sachs’ US Conviction List, while Amgen (AMGN) and Global-E Online (GLBE) are out. Goldman Sachs Director of Americas Equity Research Steve Kron comes on to talk more about these picks and the selection process for the firm’s conviction list. “Consumers are in…
Good morning, Quartz readers! HERE’S WHAT YOU NEED TO KNOW Elon Musk is mad he didn’t get an invite to California’s upcoming EV party. The Tesla CEO is upset that market share limitations on a tax credit in the works would block his company from the benefit. Donald Trump’s best and worst cabinet picks, according…
The recent volatility in key GLP-1 stocks has put the spotlight on the anxiety Wall Street has about the weight loss market. The market is huge — a potential $150 billion a year by the end of the decade — and any financial miss, or negative data of any kind, will trigger outsized sell-offs. This…